The history of Eukarÿs is closely tied to C3P3 – our core expression technology developed by scratch by the company. C3P3 is the first ever non-viral artificial eukaryotic expression system. It synthesizes autonomously and at high rate messenger RNA(s) of interest (mRNA) in the host cell cytoplasm, which leads to high production levels of the corresponding protein(s). The crucial role of mRNA in the flow of genetic information explains that the C3P3 system has a wide range of in vivo therapeutic and non-therapeutic applications in the entire eukaryotic world.

Until late 2000s, the C3P3 technology was only a theoretical concept, which was nearly impossible to develop due to the amazing complexity of eukaryotic post-transcriptional mRNA modifications. Nevertheless, the rapid emergence of synthetic biology and growing insights of the roles of eukaryotic mRNA modifications made C3P3 technically possible, although relatively complex to develop. Eukarÿs therefore started its development from scratch late 2000s and generated in early 2010 the very first prototype of the C3P3 expression system – C3P3-G0.

The development of the first highly processive generation of C3P3 (C3P3-G1) took over five years and was completed late 2015. This development consisted of optimizing step-by-step the 20 blocks that makes the entire C3P3-G1 system. C3P3-G1 has shown excellent performances for the transcription of CpG-free DNA templates, which are preferably used for human therapeutics. C3P3-G1 availability made possible the launch of our synthetic gene therapy approach – an entirely novel type of treatment, which is at the same time safe, efficient and suitable to most human disorders. The important unmet medical needs in field of hepatology led to the decision to focus our developments on the treatment of severe liver disorders. A proof of concept was rapidly obtained for EUK-LPR, our first synthetic gene therapy approach.


Simultaneously, Eukarÿs has completed the development of the 2nd generation of C3P3 for mammals by mid-2017, and then has launched the third generation of the C3P3 system (C3P3-G3) which is currently used. C3P3-G3 has a much greater complexity than the initial prototypes and has excellent performances for the expression of both with CpG-rich and CpG-free DNA templates. These significant improvements allowed the development of bioproduction tools. These tools can be used for the production of both recombinant proteins and viruses, with greater performances and shorter duration of development than the existing technology.

Today, Eukarÿs is a preclinical-stage biotechnology company aiming to extend its synthetic gene therapy approach to other therapeutic fields, such as deficiencies of secreted proteins, oncology and others. Eukarÿs exploits and license-out its C3P3 tools for the bioproduction of recombinant proteins and viruses bioproduction.

Eukarÿs SAS – Génopole campus

4 rue Pierre Fontaine

921058 Evry Cedex